1
10X Genomics Inc (TXG)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
$54.99
-3.20 (-5.50%)
Market Cap: $7.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
10X Genomics Inc (TXG) Valuation Multiples
10X Genomics (TXG) trades at 11.6x sales and 8.6x book value. Its P/S of 11.6x is above its 5-year median of 7.3x.
Current Multiples
Its free cash flow yield is 1.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 11.6x |
| Price to book | 8.6x |
| Price to FCF | 76.7x |
| EV/FCF | 71.1x |
| PEG | N/A |
| FCF yield | 1.3% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 11.6x | 7.3x | N/A |
| P/B | 8.6x | 5.4x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 2.8x in 2024 to 48.3x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $16.31 | 70.9x | 3.2x | 2.6x |
| 2024 | $14.36 | N/A | 2.8x | 2.5x |
| 2023 | $55.96 | N/A | 10.6x | 9.0x |
| 2022 | $36.44 | N/A | 8.0x | 5.2x |
| 2021 | $148.96 | N/A | 33.5x | 20.4x |
| 2020 | $141.60 | N/A | 48.3x | 20.6x |
| 2019 | $76.25 | N/A | 7.6x | 17.4x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TXG
Is TXG stock overvalued?
GNG's valuation label for TXG is Overvalued.
What is TXG's price to sales ratio?
10X Genomics has a price to sales ratio of 11.6x.
TXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts